<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857515</url>
  </required_header>
  <id_info>
    <org_study_id>CT-101-CLS-001</org_study_id>
    <nct_id>NCT04857515</nct_id>
  </id_info>
  <brief_title>Clinical Learning Study for a Mobile Smoking Cessation Program</brief_title>
  <official_title>An Exploratory, Observational, Open-label, Remote Study of Clickotine: A Digital Therapeutic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Click Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Click Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study are to obtain learnings regarding the Digital Therapeutic (DTx)&#xD;
      experience of Clickotine, including acceptability and preference of the overall program and&#xD;
      specific DTx components, as well as to obtain learnings related to adult participants' use of&#xD;
      the DTx for smoking cessation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Actual">June 28, 2021</completion_date>
  <primary_completion_date type="Actual">June 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The main outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention (DTx).</measure>
    <time_frame>4 Months</time_frame>
    <description>General acceptability of the DTx will be evaluated via surveys for all participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The main outcome of the Clickotine Learning Study is to determine engagement with the digital intervention (DTx).</measure>
    <time_frame>4 Months</time_frame>
    <description>Engagement with the digital intervention will be measured via app use for all participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The main outcome of the Clickotine Learning Study is to evaluate attitudes and beliefs regarding the digital intervention.</measure>
    <time_frame>4 Months</time_frame>
    <description>Attitudes and beliefs regarding the digital intervention will be evaluated by interview for selected participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome of the Clickotine Learning Study is to measure engagement levels with the digital intervention for cigarette smokers as compared to dual-users</measure>
    <time_frame>4 Months</time_frame>
    <description>These engagement levels will be measured via app use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The secondary outcome of the Clickotine Learning Study is to determine acceptability of the digital intervention for cigarette users as compared to dual-users</measure>
    <time_frame>4 Months</time_frame>
    <description>Acceptability of the digital intervention will be evaluated via survey</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Smoking Behaviors</condition>
  <condition>Smoking Reduction</condition>
  <condition>Smoking, Cigarette</condition>
  <condition>Smoking</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Cigarette Smokers</arm_group_label>
    <description>Adult cigarette smokers who only smoke combustible cigarettes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual-Users</arm_group_label>
    <description>Adult smokers who smoke both combustible cigarettes and vape</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ClickotineÂ®</intervention_name>
    <description>Clickotine is a DTx that contains behavior modification techniques that include controlled breathing, social engagement, personalized messaging, medication access and adherence, digital diversions, and financial incentives.</description>
    <arm_group_label>Cigarette Smokers</arm_group_label>
    <arm_group_label>Dual-Users</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Age: 18+ US Resident Fluent in english&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Age 18 and older.&#xD;
&#xD;
          -  For cigarette smokers: Smokes at least 5 cigarettes a day. For dual-users: Smokes&#xD;
             cigarettes AND uses e-cigarettes, with the following additional criteria:&#xD;
&#xD;
               -  Smokes at least 5 cigarettes a day&#xD;
&#xD;
               -  Vaping sessions, when they occur, must be for at least 10 minutes (15 puffs)&#xD;
&#xD;
          -  Fluent in written and spoken English (confirmed by ability to read and comprehend the&#xD;
             informed consent form)&#xD;
&#xD;
          -  Lives in the United States.&#xD;
&#xD;
          -  Is the solo user of an iPhone with iPhone operating system (iOS)13 or greater&#xD;
             capabilities or a smart phone with an Android operating system (OS) 9 or greater&#xD;
             capabilities.&#xD;
&#xD;
          -  Has an active email address.&#xD;
&#xD;
          -  Willing and able to receive SMS text messages on their smartphone and email messages.&#xD;
&#xD;
          -  Have access to internet connection during the study duration.&#xD;
&#xD;
          -  Able to confirm download of installed DTx on baseline date.&#xD;
&#xD;
          -  Willing and able to comply with study protocol and assessments.&#xD;
&#xD;
          -  Is willing and able to self-identify sessions of cigarette smoking (1 or more&#xD;
             consecutive cigarettes) or vaping (approximately 15 puffs or around 10 minutes in&#xD;
             duration) and log those sessions.&#xD;
&#xD;
          -  Self-reported comfort with and ability to use smartphone apps/programs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of Clickotine.&#xD;
&#xD;
          -  Currently using a software app for smoking cessation.&#xD;
&#xD;
          -  Lifetime diagnosis of schizophrenia, psychotic disorder, or pervasive developmental&#xD;
             disorders, as per participant self-report.&#xD;
&#xD;
          -  Any unstable medical illnesses including hepatic, renal, gastroenterological,&#xD;
             respiratory, cardiovascular, endocrine, neurologic (including history of severe head&#xD;
             injury with loss of consciousness), immunologic, or hematologic disease, as per&#xD;
             participant self-report.&#xD;
&#xD;
          -  Other significant medical condition that, in the opinion of the Investigator or study&#xD;
             sponsor, may cofound the interpretation of device efficacy, safety, and tolerability.&#xD;
&#xD;
          -  Current use of tobacco-containing products other than cigarettes or e-cigarettes (e.g.&#xD;
             snuff, chewing tobacco, cigars, or pipes).&#xD;
&#xD;
          -  Does not have or is unwilling to create a PayPal account&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Click Therapeutics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking Cessation</keyword>
  <keyword>Smoking Cessation Program</keyword>
  <keyword>Smoking Cessation Digital Therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

